目的 探討血府逐瘀片對(duì)老年2型糖尿病（T2DM）聯(lián)合慢性阻塞性肺疾?。–OPD）患者肺功能、氧化應(yīng)激指標(biāo)和炎癥指標(biāo)的影響。方法 選擇河南省三門峽市中醫(yī)院自2016年3月—2018年12月收治的老年T2DM合并COPD患者95例作為研究對(duì)象，根據(jù)入院先后順序?qū)⒒颊叻譃閷?duì)照組（47例）和觀察組（48例）。對(duì)照組行T2DM及COPD基礎(chǔ)治療，觀察組在對(duì)照組治療基礎(chǔ)上加用血府逐瘀片，6片/次，2次/d。兩組均治療2個(gè)月。對(duì)比兩組治療前后的肺功能、氧化應(yīng)激指標(biāo)、炎癥指標(biāo)水平及治療期間的不良反應(yīng)。結(jié)果 治療后，兩組的用力肺活量（FVC）、肺活量（VC）、用力呼氣容積（FEV1）、最大自主通氣量（MVV）、FEV1/FVC水平均明顯升高（P<0.05），且觀察組肺功能指標(biāo)水平顯著高于對(duì)照組（P<0.05）。治療后，兩組的超氧化物歧化酶（SOD）水平均明顯上升，且觀察組明顯高于對(duì)照組（P<0.05）；兩組的丙二醛（MDA）、白細(xì)胞介素-6（IL-6）、超敏C反應(yīng)蛋白（hs-CRP）水平明顯下降，且觀察組明顯低于對(duì)照組（P<0.05）。觀察組的不良反應(yīng)發(fā)生率高于對(duì)照組，但組間對(duì)比無統(tǒng)計(jì)學(xué)意義。結(jié)論 血府逐瘀片可能通過抑制老年T2DM合并COPD患者機(jī)體的氧化應(yīng)激反應(yīng)，降低炎癥反應(yīng)，從而改善其肺通氣功能。

Objective To investigate the effect of Xuefu Zhuyu Tablets on pulmonary function, oxidative stress, and inflammatory factors in elderly patients with T2DM combined with COPD. Methods A total of 95 elderly patients with T2DM combined COPD in Traditional Chinese Medicine Hospital of Sanmenxia City from March 2016 to December 2018 were selected as study subjects, and the patients were divided into control group (47 cases) and observation group (48 cases) according to the order of admission. Patients in the control group was treated with T2DM and COPD basic treatment, and patients in the observation group were po administered with Xuefu Zhuyu Tablets on the basis of the control group, 6 tablets/time, twice daily. Both groups were treated for 2 months. After treatment, the pulmonary function, oxidative stress, inflammation, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the levels of FVC, VC, FEV1, MVV, and FEV1/FVC in two groups were significantly increased (P<0.05), and the pulmonary function indexes in the observation group were significantly higher than those in the control group (P<0.05). After treatment, SOD level in two groups was increased significantly, and the observation group was higher than that in the control group (P<0.05). And the levels of MDA, IL-6, and hs-CRP in two groups were significantly decreased, and the indexes in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was higher than that in the control group, but there was no statistically significant difference between two groups. Conclusion Xuefu Zhuyu Tablets may improve pulmonary ventilation function by inhibiting oxidative stress response and reducing inflammation in elderly patients with T2DM combined with COPD.

R974;R975